The collagen-binding leech products rLAPP and calin prevent both von Willebrand factor and alpha2beta1(GPIa/IIa)-I-domain binding to collagen in a different manner
Research article published in Thromb Haemost (1999)
Abstract
Calin and rLAPP are two natural inhibitors that are able to inhibit the vWF-binding and platelet adhesion to collagen both under static and flow conditions. In this study we demonstrate that both rLAPP and Calin prevent alpha2I-domain binding to human collagen type I with an IC50 of 5 microg/ml. However, although both vWF and alpha2I-domain binding to collagen is prevented by rLAPP and Calin, the latter two do not bind to the same collagen site since Calin only partially could compete with rLAPP for binding to collagen. Also vWF and the alpha2I-domain were unable to compete completely with each other for the binding to collagen. So the following hypothesis can be made: the binding sites of vWF and of the alpha2I-domain on human collagen type I are different but close to each other since rLAPP could inhibit both interactions, and thus should bind to an overlapping epitope. The Calin preparation on the other hand may still contain two active principles, one interfering with vWF-binding, the other with the alpha2I-domain-binding to collagen.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
rLAPP and Calin both prevent alpha2I-domain binding to human collagen type I with IC50 of 5 microg/ml; the two inhibitors do not bind to the same collagen site since Calin only partially competes with rLAPP.
Por qué esto importa para la hirudoterapia
Este estudio in vitro examinó dos inhibidores derivados de sanguijuela que se unen al colágeno, LAPP recombinante (rLAPP) y Calin, y demostró que ambos evitan que el dominio I de la integrina plaquetaria α2β1 (GPIa/IIa) se una al colágeno tipo I humano (IC50 ~5 µg/ml), además de bloquear la unión del factor de von Willebrand al colágeno, mientras que la evidencia de mapeo sugiere que actúan en sitios de colágeno diferentes pero superpuestos. Es directamente relevante para la narrativa de descubrimiento de fármacos del secretoma de la sanguijuela porque caracteriza cómo las proteínas salivales específicas de la sanguijuela interrumpen los primeros pasos de la adhesión plaquetaria — un mecanismo antitrombótico distinto de la inhibición de la trombina por hirudin. Advertencia honesta: se trata de bioquímica mecanicista en moléculas aisladas bajo condiciones estáticas y de flujo, no de un estudio en animales o clínico, por lo que explica cómo funcionan estas proteínas de sanguijuela pero no dice nada sobre la seguridad, la dosificación o el beneficio terapéutico en los pacientes.
Citación
The collagen-binding leech products rLAPP and calin prevent both von Willebrand factor and alpha2beta1(GPIa/IIa)-I-domain binding to collagen in a different manner.
Depraetere H et al. · Thromb Haemost, 1999
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026